Updates in NMOSD and MOGAD Diagnosis and Treatment

Cacciaguerra, Laura; Flanagan, Eoin P.

doi:10.1016/j.ncl.2023.06.009

Cited by 4 publications

(1 citation statement)

References 157 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diagnosing MOGAD has traditionally relied on clinical judgment, supported by serology testing for MOG antibodies. Given its nature as a demyelinating disorder, there is a significant overlap with NMOSD and MS in both clinical presentation and neuroradiology findings [19,20]. This underscores the need for precise diagnostic criteria for MOGAD to distinguish it from similar conditions.…”

Section: Introductionmentioning

confidence: 99%

Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings

Rechtman,

Freidman-Korn,

Zveik

et al. 2024

J Neurol

View full text Add to dashboard Cite

Introduction Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified demyelinating disorder with a diverse clinical spectrum. Diagnosing MOGAD traditionally relies on clinical judgment, highlighting the necessity for precise diagnostic criteria. Banwell et al. proposed criteria, aiming to refine the diagnostic spectrum. This study evaluates these criteria in a real-life cohort, comparing their performance with clinical judgment and describe the cohort of MOGAD patients. Methods This retrospective study, conducted at Hadassah Medical Center, included 88 patients with MOG-IgG antibodies. Patients with a positive or borderline MOG-IgG antibodies by cell-based assay were included. Demographics, clinical and MRI data were recorded. Cases were divided into definite MOGAD and Non-MOGAD groups as determined by the treating physician. We assessed the sensitivity and specificity of the new criteria in comparison to treating physicians’ evaluations. Additionally, we examined clinical differences between the MOGAD and Non-MOGAD groups. Results We observed a strong concordance (98%) between the new MOGAD criteria and treating physicians' diagnoses. Clinical disparities between MOGAD and Non-MOGAD groups included lower EDSS scores, normal MRI scans, preserved brain volume, negative OCB results, and distinct relapse patterns. Also, compared to relapsing patients, monophasic MOGAD patients have greater brain volume and a lower age at onset. Conclusion The study demonstrates robust accuracy of new MOGAD criteria, emphasizing their potential to enhance diagnostic precision. Treatment response integration into the MOGAD diagnosis is crucial, as it could aid in distinguishing MOGAD from other demyelinating disorders. Distinct clinical profiles highlight the importance of informed decisions in managing MOGAD and similar disorders.

show abstract

Section: Introductionmentioning

confidence: 99%

Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings

Rechtman,

Freidman-Korn,

Zveik

et al. 2024

J Neurol

View full text Add to dashboard Cite

show abstract

Brain and spinal cord atrophy in NMOSD and MOGAD: Current evidence and future perspectives

Lorefice,

Cortese

2024

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

Education and training in neurology: developments and future challenges

van der Meulen,

Wijnenga

2024

Euro J of Neurology

View full text Add to dashboard Cite

Background and purposeTraining and education is essential for best practice medicine and is especially important in a rapidly evolving field such as neurology. Due to improved imaging techniques and laboratory testing, there is a better understanding of the pathophysiology of diseases. As a result more treatments have become available. The most important developments in neurology over the last two decades and their effect on training and education are described. In addition, how future training should be aware of the challenges ahead of us is described.MethodsThis is a narrative review describing developments and challenges based on personal experience and the literature.ResultsDue to major developments in radiological and immunological testing, major changes have been seen in different subspecialties of neurology, including but not limited to, the treatment of ischaemic stroke, the development of new entities in the field of demyelinating diseases and auto‐immune encephalitis, and diffuse glioma. These developments challenge the education and training in neurology with, ahead of us, technological developments, an aging population, and potentially more superspecialization.ConclusionAlthough there are differences in the training curricula between European countries, the developments and future challenges within the field of neurology are very similar. In the development of future curricula it is important to face these developments and challenges and to adapt to them.

show abstract

Updates in NMOSD and MOGAD Diagnosis and Treatment

Cited by 4 publications

References 157 publications

Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings

Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings

Brain and spinal cord atrophy in NMOSD and MOGAD: Current evidence and future perspectives

Education and training in neurology: developments and future challenges

Contact Info

Product

Resources

About